Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

Th3M4skedSt0nker Mar. 16 at 3:01 AM

$KYTX is an easy 100%-200% this year alone. Might happen actually very fast within next 3 months with the given catalyst pipeline. Strong institutional ownership. Strong insider confidence with recent market buys. Only retail is still sleeping on this beauty...compare no. of watchers to $SLS $CING $QURE Good Luck Dear Ladies and Gentlemen 💲 💲💲

1 · Reply

Madmortigan Mar. 13 at 11:06 PM

$KYTX This seems to be moving upwards regardless of the sector movement as well 🤷‍♂️

0 · Reply

Madmortigan Mar. 13 at 10:08 PM

$KYTX Making gains in a river of red!

0 · Reply

michaftm Mar. 11 at 11:00 AM

$KYTX The market still doesn't realize this company is going to have several monopolies across different diseases. If they don't get bought out, this is a future giant with a $20B+ market cap by 2035 🚀

1 · Reply

hbkstockislife Mar. 10 at 4:38 PM

$KYTX good pump Article

1 · Reply

Th3M4skedSt0nker Mar. 10 at 3:00 PM

$QURE might need to wait for its BLA while $KYTX just announced they expect it in H1 2026. Way undervalued...

0 · Reply

Th3M4skedSt0nker Mar. 10 at 2:02 PM

$KYTX 💲💲💲

0 · Reply

blocktrade Mar. 9 at 10:00 PM

$KYTX catalyst coming during the April 18-22 presentation at the American Academy of Neurology

0 · Reply

Th3M4skedSt0nker Mar. 9 at 8:17 PM

$KYTX agreed. Though retail has kind of a blind spot on Kyverna anyway...the bigger might be the explosion once they get the BLA 💲💲💲

0 · Reply

ak123456790 Mar. 9 at 6:49 PM

$KYTX Some big fund is accumulating cheap shares with the help of MMs… See the price and volume.. quietly and with patience they do that every day .. They don’t want big upsides and they try to hide this gem from retail! The float is very small and they want shares.. It takes weeks for a big fund to buy the shares they want and that is why you see this weird steady price and volume! See you in a month at the conference news were the share price will explode !

0 · Reply

Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 5, 2026, 4:21 PM EST - 11 days ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 3, 2026, 8:00 AM EST - 13 days ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

Mar 3, 2026, 1:02 AM EST - 14 days ago

Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution

Feb 24, 2026, 8:00 AM EST - 20 days ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Feb 3, 2026, 8:00 AM EST - 5 weeks ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 12, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 2 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 18, 2025, 2:48 PM EST - 3 months ago

Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies

Dec 17, 2025, 11:59 AM EST - 3 months ago

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

Dec 17, 2025, 9:24 AM EST - 3 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 16, 2025, 3:46 PM EST - 3 months ago

Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing

Dec 16, 2025, 8:06 AM EST - 3 months ago

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

LWLG

Dec 15, 2025, 4:01 PM EST - 3 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 12:06 PM EST - 3 months ago

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome

Dec 15, 2025, 6:42 AM EST - 3 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 3 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 3 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Dec 8, 2025, 9:00 AM EST - 3 months ago

Stock Picks From Seeking Alpha's November 2025 New Analysts

ABEV CEG CEPU EAT GLXY GT KOF

Nov 14, 2025, 2:24 AM EST - 4 months ago

Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential

Nov 12, 2025, 4:05 PM EST - 4 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 4 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 4 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 6:30 AM EDT - 4 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 5 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 6 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 6 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Aug 28, 2025, 8:00 AM EDT - 7 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 7 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 20, 2025, 3:29 PM EDT - 7 months ago

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Aug 12, 2025, 4:02 PM EDT - 7 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 8 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

May 28, 2025, 4:02 PM EDT - 10 months ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 3:42 PM EDT - 10 months ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 13, 2025, 4:02 PM EDT - 10 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 21, 2025, 11:29 AM EDT - 1 year ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 6, 2025, 1:51 PM EST - 1 year ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 5, 2025, 11:54 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Th3M4skedSt0nker Mar. 16 at 3:01 AM

1 · Reply

Madmortigan Mar. 13 at 11:06 PM

$KYTX This seems to be moving upwards regardless of the sector movement as well 🤷‍♂️

0 · Reply

Madmortigan Mar. 13 at 10:08 PM

$KYTX Making gains in a river of red!

0 · Reply

michaftm Mar. 11 at 11:00 AM

1 · Reply

hbkstockislife Mar. 10 at 4:38 PM

$KYTX good pump Article

1 · Reply

Th3M4skedSt0nker Mar. 10 at 3:00 PM

$QURE might need to wait for its BLA while $KYTX just announced they expect it in H1 2026. Way undervalued...

0 · Reply

Th3M4skedSt0nker Mar. 10 at 2:02 PM

$KYTX 💲💲💲

0 · Reply

blocktrade Mar. 9 at 10:00 PM

$KYTX catalyst coming during the April 18-22 presentation at the American Academy of Neurology

0 · Reply

Th3M4skedSt0nker Mar. 9 at 8:17 PM

$KYTX agreed. Though retail has kind of a blind spot on Kyverna anyway...the bigger might be the explosion once they get the BLA 💲💲💲

0 · Reply

ak123456790 Mar. 9 at 6:49 PM

0 · Reply

Amitzohar Mar. 9 at 4:19 PM

$KYTX What do you think about everything that was said at the Leerink Global Healthcare Conference?”

1 · Reply

specctham Mar. 9 at 10:35 AM

$KYTX

0 · Reply

ak123456790 Mar. 6 at 1:55 PM

$KYTX The share price will explode on the conferences next month! Best in class drugs, billions of sales...BO late of 2026 or mid 2027 !

2 · Reply

OpenOutcrier Mar. 6 at 1:12 PM

$KYTX (+2.5% pre) Kyverna to present stiff person syndrome trial data at AAN 2026 - SI https://ooc.bz/l/95786

0 · Reply

Amitzohar Mar. 6 at 12:20 PM

$KYTX statistically significant clinical benefit across all primary and secondary endpoints, including reversing progressive disability” 🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑🤑

0 · Reply

hbkstockislife Mar. 5 at 4:00 PM

$KYTX so xbi up 2% we are up 10%..xbi down 2% and we are down .0008% lmao ..nothing can bring this down now ..nothing ..

1 · Reply

Guadangia Mar. 4 at 10:43 PM

$KYTX my fav stock in the CART ecosystem. Insiders buying, whenever they want will visit the 35-45 area

0 · Reply

Th3M4skedSt0nker Mar. 4 at 7:34 PM

$KYTX look at that beautiful 1 year chart. Soon this will explode again into new heights 💲💲💲

0 · Reply

dragonsoup Mar. 4 at 3:33 PM

$KYTX ez monry

0 · Reply

Amitzohar Mar. 4 at 3:20 PM

$KYTX

0 · Reply

Th3M4skedSt0nker Mar. 2 at 8:40 PM

$KYTX 💲💲💲

1 · Reply

Madmortigan Feb. 26 at 8:45 PM

$KYTX Sideways is better than down 🤷‍♂️

0 · Reply

Market Cap	391.97M
Revenue (ttm)	0.00
Net Income (ttm)	-127.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	429,700
Avg Vol	766,838
Day's Range	N/A - N/A
Shares Out	43.80M
Stochastic %K	58%
Beta	3.32
Analysts	Strong Sell
Price Target	$28.20